Skip to main content
Top
Published in: The Journal of Behavioral Health Services & Research 4/2020

01-10-2020 | Naltrexone

Organizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use

Authors: Nora Jacobson, PhD, Julie Horst, MBA, Liam Wilcox-Warren, BS, Alex Toy, BS, Hannah K. Knudsen, PhD, Randy Brown, MD, PhD, Eric Haram, BS, LADC, Lynn Madden, PhD, MPA, Todd Molfenter, PhD

Published in: The Journal of Behavioral Health Services & Research | Issue 4/2020

Login to get access

Abstract

Medication for opioid use disorder (MOUD) is a key strategy for addressing the opioid use disorder crisis, yet gaps in MOUD provision impede this strategy’s benefits. The research reported here sought to understand what distinguishes low- and high-performing organizations in building and using capacity to provide MOUD. As part of a mixed methods MOUD implementation trial, semi-structured telephone interviews were conducted with personnel from low- and high-performing MOUD-providing organizations. Seventeen individuals from 17 organizations were interviewed. Findings demonstrate the importance of individual, organization, and community-level factors in supporting the building and use of MOUD capacity. Low- and high-performing organizations showed different patterns of facilitators and barriers during the implementation process. The key difference between low- and high-performing organizations was the level of organizational functioning. A better understanding of an organization’s assets and deficits at the individual, organizational, and community levels would allow decision-makers to tailor their approaches to MOUD implementation.
Literature
2.
go back to reference Florence CS, Zhou C, Luo F, et al. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Medical Care. 2016;54(10):901-906.PubMedPubMedCentral Florence CS, Zhou C, Luo F, et al. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Medical Care. 2016;54(10):901-906.PubMedPubMedCentral
4.
go back to reference Lynch S, Sherman L, Snyder SM, et al. Trends in infants reported to child welfare with neonatal abstinence syndrome (NAS). Children and Youth Services Review. 2018;86:135-141. Lynch S, Sherman L, Snyder SM, et al. Trends in infants reported to child welfare with neonatal abstinence syndrome (NAS). Children and Youth Services Review. 2018;86:135-141.
5.
go back to reference Volkow ND, Wargo EM. Overdose prevention through medical treatment of opioid use disorders. Annals of Internal Medicine. 2018;169(3):190-192.PubMed Volkow ND, Wargo EM. Overdose prevention through medical treatment of opioid use disorders. Annals of Internal Medicine. 2018;169(3):190-192.PubMed
7.
go back to reference Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harvard Review of Psychiatry. 2015;23(2):63-75.PubMed Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harvard Review of Psychiatry. 2015;23(2):63-75.PubMed
8.
go back to reference Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet (London, England). 2011;377(9776):1506-1513. Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet (London, England). 2011;377(9776):1506-1513.
9.
go back to reference Hser YI, Evans E, Huang D, et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction (Abingdon, England). 2016;111(4):695-705. Hser YI, Evans E, Huang D, et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction (Abingdon, England). 2016;111(4):695-705.
10.
go back to reference Lee JD, Friedmann PD, Kinlock TW, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. New England Journal of Medicine. 2016;374(13):1232-1242.PubMed Lee JD, Friedmann PD, Kinlock TW, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. New England Journal of Medicine. 2016;374(13):1232-1242.PubMed
11.
go back to reference Mozurkewich EL, Rayburn WF. Buprenorphine and methadone for opioid addiction during pregnancy. Obstetrics and Gynecology Clinics of North America. 2014;41(2):241-253.PubMed Mozurkewich EL, Rayburn WF. Buprenorphine and methadone for opioid addiction during pregnancy. Obstetrics and Gynecology Clinics of North America. 2014;41(2):241-253.PubMed
12.
go back to reference Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Annals of Internal Medicine. 2018;169(3):137-145.PubMedPubMedCentral Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Annals of Internal Medicine. 2018;169(3):137-145.PubMedPubMedCentral
13.
go back to reference Ma J, Bao YP, Wang RJ, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Molecular Psychiatry. 2019;24(12):1868-1883.PubMed Ma J, Bao YP, Wang RJ, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Molecular Psychiatry. 2019;24(12):1868-1883.PubMed
14.
go back to reference American Society of Addiction Medicine (ASAM). The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction involving Opioid Use. Chevy Chase: American Society of Addiction Medicine, 2015. American Society of Addiction Medicine (ASAM). The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction involving Opioid Use. Chevy Chase: American Society of Addiction Medicine, 2015.
15.
go back to reference World Health Organization. Essential Medicines: WHO Model List (revised March 2005). Geneva: World Health Organization, 2003. World Health Organization. Essential Medicines: WHO Model List (revised March 2005). Geneva: World Health Organization, 2003.
16.
go back to reference Volkow ND, Frieden TR, Hyde PS, et al. Medication-assisted therapies--tackling the opioid-overdose epidemic. New England Journal of Medicine. 2014;370(22):2063-2066.PubMed Volkow ND, Frieden TR, Hyde PS, et al. Medication-assisted therapies--tackling the opioid-overdose epidemic. New England Journal of Medicine. 2014;370(22):2063-2066.PubMed
17.
go back to reference Jones CM, Campopiano M, Baldwin G, et al. National and state treatment need and capacity for opioid agonist medication-assisted treatment. American Journal of Public Health. 2015;105(8):e55-63.PubMedPubMedCentral Jones CM, Campopiano M, Baldwin G, et al. National and state treatment need and capacity for opioid agonist medication-assisted treatment. American Journal of Public Health. 2015;105(8):e55-63.PubMedPubMedCentral
18.
go back to reference Substance Abuse and Mental Health Services Administration (SAMHSA). National Survey of Substance Abuse Treatment Services (N-SSATS) 2016: Data on Substance Abuse Treatment Facilities. Rockville: Substance Abuse and Mental Health Services Administration, 2017. Substance Abuse and Mental Health Services Administration (SAMHSA). National Survey of Substance Abuse Treatment Services (N-SSATS) 2016: Data on Substance Abuse Treatment Facilities. Rockville: Substance Abuse and Mental Health Services Administration, 2017.
19.
go back to reference Jones CM, McCance-Katz EF. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction (Abingdon, England). 2019;114(3):471-482. Jones CM, McCance-Katz EF. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction (Abingdon, England). 2019;114(3):471-482.
20.
go back to reference Substance Abuse and Mental Health Services Administration (SAMHSA). Drug Addiction Treatment Act of 2000 (DATA 2000). Public Law No. 106–310, Title XXXV-Waiver authority for physicians who dispense or prescribe certain narcotic drugs for maintenance treatment or detoxification treatment. Rockville: Substance Abuse and Mental Health Services Administration, 2000. Substance Abuse and Mental Health Services Administration (SAMHSA). Drug Addiction Treatment Act of 2000 (DATA 2000). Public Law No. 106–310, Title XXXV-Waiver authority for physicians who dispense or prescribe certain narcotic drugs for maintenance treatment or detoxification treatment. Rockville: Substance Abuse and Mental Health Services Administration, 2000.
21.
go back to reference Tiberg F, Johnsson M, Harwigsson I, Inventors. U.S. Patent Application No. 15/520,946. 2018. Tiberg F, Johnsson M, Harwigsson I, Inventors. U.S. Patent Application No. 15/520,946. 2018.
22.
go back to reference Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients’ care. Lancet (London, England). 2003;362(9391):1225-1230. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients’ care. Lancet (London, England). 2003;362(9391):1225-1230.
23.
go back to reference Brownson RC, Colditz GA, Proctor EK, eds. Dissemination and Implementation Research in Health: Translating Science to Practice. Second ed. New York: Oxford University Press, 2017. Brownson RC, Colditz GA, Proctor EK, eds. Dissemination and Implementation Research in Health: Translating Science to Practice. Second ed. New York: Oxford University Press, 2017.
24.
go back to reference Socias ME, Volkow N, Wood E. Adopting the ‘cascade of care’ framework: an opportunity to close the implementation gap in addiction care? Addiction (Abingdon, England). 2016;111(12):2079-2081. Socias ME, Volkow N, Wood E. Adopting the ‘cascade of care’ framework: an opportunity to close the implementation gap in addiction care? Addiction (Abingdon, England). 2016;111(12):2079-2081.
25.
go back to reference Knudsen HK, Roman PM. The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources. Journal of Studies on Alcohol and Drugs. 2014;75(3):476-485.PubMedPubMedCentral Knudsen HK, Roman PM. The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources. Journal of Studies on Alcohol and Drugs. 2014;75(3):476-485.PubMedPubMedCentral
26.
go back to reference U.S. Government Accountability Office. Opioid Crisis: Status of Public Health Emergency Authorities. By Mary Denigan-Macauley, Acting Director, Health Care. Washington, DC: U.S. Government Accountability Office, September 26, 2018. U.S. Government Accountability Office. Opioid Crisis: Status of Public Health Emergency Authorities. By Mary Denigan-Macauley, Acting Director, Health Care. Washington, DC: U.S. Government Accountability Office, September 26, 2018.
27.
go back to reference Aletraris L, Edmond MB, Paino M, et al. Counselor training and attitudes toward pharmacotherapies for opioid use disorder. Substance Abuse : official publication of the Association for Medical Education and Research in Substance Abuse. 2016;37(1):47-53. Aletraris L, Edmond MB, Paino M, et al. Counselor training and attitudes toward pharmacotherapies for opioid use disorder. Substance Abuse : official publication of the Association for Medical Education and Research in Substance Abuse. 2016;37(1):47-53.
28.
go back to reference Uebelacker LA, Bailey G, Herman D, et al. Patients’ beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification. Journal of Substance Abuse Treatment. 2016;66:48-53.PubMedPubMedCentral Uebelacker LA, Bailey G, Herman D, et al. Patients’ beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification. Journal of Substance Abuse Treatment. 2016;66:48-53.PubMedPubMedCentral
29.
go back to reference Hutchinson E, Catlin M, Andrilla CHA, et al. Barriers to primary care physicians prescribing buprenorphine. The Annals of Family Medicine. 2014;12(2):128-133.PubMed Hutchinson E, Catlin M, Andrilla CHA, et al. Barriers to primary care physicians prescribing buprenorphine. The Annals of Family Medicine. 2014;12(2):128-133.PubMed
30.
go back to reference Molfenter T. The pressing shortage of buprenorphine prescribers and the pending role of telemedicine. Addiction Science & Clinical Practice. 2015;10(Suppl 1):A40. Molfenter T. The pressing shortage of buprenorphine prescribers and the pending role of telemedicine. Addiction Science & Clinical Practice. 2015;10(Suppl 1):A40.
31.
go back to reference Andrilla CHA, Coulthard C, Larson EH. Barriers rural physicians face prescribing buprenorphine for opioid use disorder. Annals of Family Medicine. 2017;15(4):359-362.PubMedPubMedCentral Andrilla CHA, Coulthard C, Larson EH. Barriers rural physicians face prescribing buprenorphine for opioid use disorder. Annals of Family Medicine. 2017;15(4):359-362.PubMedPubMedCentral
32.
go back to reference Alanis-Hirsch K, Croff R, Ford JH, 2nd, et al. Extended-release naltrexone: a qualitative analysis of barriers to routine use. Journal of Substance Abuse Treatment. 2016;62:68-73.PubMed Alanis-Hirsch K, Croff R, Ford JH, 2nd, et al. Extended-release naltrexone: a qualitative analysis of barriers to routine use. Journal of Substance Abuse Treatment. 2016;62:68-73.PubMed
33.
go back to reference Molfenter T, Sherbeck C, Starr S, et al. Payer policy behavior towards opioid pharmacotherapy treatment in Ohio. Journal of Addiction Medicine. 2018;12(2):85-91.PubMed Molfenter T, Sherbeck C, Starr S, et al. Payer policy behavior towards opioid pharmacotherapy treatment in Ohio. Journal of Addiction Medicine. 2018;12(2):85-91.PubMed
34.
go back to reference Molfenter T, Knudsen HK, Brown R, et al. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial. Implementation Science. 2017;12(1):135.PubMed Molfenter T, Knudsen HK, Brown R, et al. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial. Implementation Science. 2017;12(1):135.PubMed
35.
go back to reference Proctor E, Silmere H, Raghavan R, et al. Outcomes for Implementation Research: Conceptual Distinctions, Measurement Challenges, and Research Agenda. Administration and Policy in Mental Health. 2011;38(2):65-76.PubMed Proctor E, Silmere H, Raghavan R, et al. Outcomes for Implementation Research: Conceptual Distinctions, Measurement Challenges, and Research Agenda. Administration and Policy in Mental Health. 2011;38(2):65-76.PubMed
36.
go back to reference Scott SD, Plotnikoff RC, Karunamuni N, et al. Factors influencing the adoption of an innovation: an examination of the uptake of the Canadian Heart Health Kit (HHK). Implementation Science. 2008;3:41.PubMed Scott SD, Plotnikoff RC, Karunamuni N, et al. Factors influencing the adoption of an innovation: an examination of the uptake of the Canadian Heart Health Kit (HHK). Implementation Science. 2008;3:41.PubMed
37.
go back to reference Schuman-Olivier Z, Connery H, Griffin ML, et al. Clinician beliefs and attitudes about buprenorphine/naloxone diversion. The American Journal on Addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 2013;22(6):574-580.PubMedCentral Schuman-Olivier Z, Connery H, Griffin ML, et al. Clinician beliefs and attitudes about buprenorphine/naloxone diversion. The American Journal on Addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 2013;22(6):574-580.PubMedCentral
38.
go back to reference Thomas C, Reif S, Haq S, et al. Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists. Psychiatric Services. 2008;59(8):909-916.PubMed Thomas C, Reif S, Haq S, et al. Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists. Psychiatric Services. 2008;59(8):909-916.PubMed
39.
go back to reference Fitzgerald J, McCarty D. Understanding attitudes toward use of medication in substance abuse treatment: a multilevel approach. Psychological Services. 2009;6(1):74.PubMedPubMedCentral Fitzgerald J, McCarty D. Understanding attitudes toward use of medication in substance abuse treatment: a multilevel approach. Psychological Services. 2009;6(1):74.PubMedPubMedCentral
40.
go back to reference Aarons GA, Green AE, Trott E, et al. The roles of system and organizational leadership in system-wide evidence-based intervention sustainment: a mixed-method study. Administration and Policy in Mental Health. 2016;43(6):991-1008.PubMedPubMedCentral Aarons GA, Green AE, Trott E, et al. The roles of system and organizational leadership in system-wide evidence-based intervention sustainment: a mixed-method study. Administration and Policy in Mental Health. 2016;43(6):991-1008.PubMedPubMedCentral
41.
go back to reference Stetler CB, Ritchie JA, Rycroft-Malone J, et al. Leadership for evidence-based practice: strategic and functional behaviors for institutionalizing EBP. Worldviews on Evidence-Based Nursing. 2014;11(4):219-226.PubMed Stetler CB, Ritchie JA, Rycroft-Malone J, et al. Leadership for evidence-based practice: strategic and functional behaviors for institutionalizing EBP. Worldviews on Evidence-Based Nursing. 2014;11(4):219-226.PubMed
42.
go back to reference Gordon AJ, Kavanagh G, Krumm M, et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors. 2011;25(2):215-224. Gordon AJ, Kavanagh G, Krumm M, et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors. 2011;25(2):215-224.
43.
go back to reference Proctor EK. Leverage points for the implementation of evidence-based practice. Brief Treatment and Crisis Intervention. 2004;4(3):227. Proctor EK. Leverage points for the implementation of evidence-based practice. Brief Treatment and Crisis Intervention. 2004;4(3):227.
44.
go back to reference Huhn AS, Dunn KE. Why aren’t physicians prescribing more buprenorphine? Journal of Substance Abuse Treatment. 2017;78:1-7.PubMedPubMedCentral Huhn AS, Dunn KE. Why aren’t physicians prescribing more buprenorphine? Journal of Substance Abuse Treatment. 2017;78:1-7.PubMedPubMedCentral
45.
go back to reference Wen H, Hockenberry JM, Borders TF, et al. Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatment. Medical Care. 2017;55(4):336-341.PubMed Wen H, Hockenberry JM, Borders TF, et al. Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatment. Medical Care. 2017;55(4):336-341.PubMed
46.
go back to reference Stein BD, Sorbero M, Dick AW, et al. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211-1212.PubMedPubMedCentral Stein BD, Sorbero M, Dick AW, et al. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211-1212.PubMedPubMedCentral
47.
go back to reference Gustafson DH, Sainfort F, Eichler M, et al. Developing and testing a model to predict outcomes of organizational change. Health Services Research. 2003;38(2):751-776.PubMedPubMedCentral Gustafson DH, Sainfort F, Eichler M, et al. Developing and testing a model to predict outcomes of organizational change. Health Services Research. 2003;38(2):751-776.PubMedPubMedCentral
48.
go back to reference Weiner BJ, Lewis MA, Linnan LA. Using organization theory to understand the determinants of effective implementation of worksite health promotion programs. Health Education Research. 2009;24(2):292-305.PubMed Weiner BJ, Lewis MA, Linnan LA. Using organization theory to understand the determinants of effective implementation of worksite health promotion programs. Health Education Research. 2009;24(2):292-305.PubMed
Metadata
Title
Organizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use
Authors
Nora Jacobson, PhD
Julie Horst, MBA
Liam Wilcox-Warren, BS
Alex Toy, BS
Hannah K. Knudsen, PhD
Randy Brown, MD, PhD
Eric Haram, BS, LADC
Lynn Madden, PhD, MPA
Todd Molfenter, PhD
Publication date
01-10-2020
Publisher
Springer US
Published in
The Journal of Behavioral Health Services & Research / Issue 4/2020
Print ISSN: 1094-3412
Electronic ISSN: 2168-6793
DOI
https://doi.org/10.1007/s11414-020-09706-4

Other articles of this Issue 4/2020

The Journal of Behavioral Health Services & Research 4/2020 Go to the issue